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ABSTRACT
OBJECTIVE: The objective of this EBM review is to determine whether or not Tamoxifen 
prophylaxis is effective in reducing the incidence of breast cancer in woman who are at high risk. 
STUDY DESIGN: Review of three English language primary studies published from 2005 to 
2007.
DATA SOURCE: Three double-blind randomized control trials found using the PubMed and 
Cochrane database.
OUTCOME MEASURED: The primary outcome by all three studies included incidence of 
breast cancer.
RESULTS: Three double- blind randomized controlled trials were included in this review.  Study 
by Powles et al showed statistically significant  reduction in the incidents of breast cancer in the 
tamoxifen arm compared to placebo group. The second study by Cuzick et al showed the risk -
reducing effect of tamoxifen appears to persist for at least 10 years. The third study by Fisher et 
al showed the rate of invasive breast cancer was reduced from 42.5 per 1000 women in the 
placebo group to 24.8 per 1000 in the tamoxifen group.
CONCLUSION: The result of three RTC’s showed that use of tamoxifen prophylaxis for breast 
cancer provides risk-reducing effect in women at high risk.  
KEY WORDS: tamoxifen prophylaxis and breast cancer, breast cancer prevention.
INTRODUCTION
 Breast cancer is the most common cancer among American women. About 1 in 8 women 
in the United States will develop breast cancer. It is the second leading cause of death in women4. 
Most women that are affected by breast cancer do not have any family history of breast cancer, 
but women who does have an significant risk of developing breast cancer during their lifetime. 
 Woman that have family history often inherit BRCA1 and BRCA2 gene from either 
mother or father. Women with these mutations have a 55-65% risk of developing breast cancer 
by age of 70.4 The focus of this study will be patients that are at high risk of breast cancer. 
 In 2014 there are about 232,670 new cases of invasive breast cancer and 10 % of all 
cancers are due to family history of breast or ovarian cancers or genes that are inherited from 
parents.4 BRCA1 and BRCA2 is the most common cause of hereditary breast cancer. Patients 
with BRCA 1 mutations has as hight as 80% lifetime risk of developing cancer. For patients with 
BRCA 2 the risk is lower around 45 %. There are also other gene mutations that can lead to 
inherited breast cancer. These mutations are ATM, TP53, CHEK2, PTEN, CDH1 but they are 
much rarer and often do not increase the risk of breast cancer as much as the BRCA genes. 6 
According to National Cancer Institute, it is estimated that 16.5 billion is spent every year on 
treating breast cancer in women. 5
 Some of the usual methods used to treat breast cancer is total mastectomy or modified 
radical mastectomy. Chemotherapy, radiation therapy and targeted therapy are some of the other 
options . In targeted therapy, monoclonal antibodies or tyrosine kinase can be used. 
DeVeau, Tamoxifen and breast cancer      1
 The topic of study is important to healthcare providers because preventive measures can 
be initiated such as using tamoxifen not only post breast cancer, but also as prophylaxis in 
women with high risk of developing breast cancer. 
OBJECTIVE
 The objective of this systemic review is to determine whether or not Tamoxifen 
prophylaxis is effective in reducing the incidence of breast cancer in woman who are at high risk. 
METHODS
 The three studies included in this review used specific criteria for selection of studies. 
The population included healthy women with high risk of developing breast cancer. All studies 
excluded any patients with breast cancer, prior invasive cancer, DVT, patients who have taken 
estrogen or progesterone therapy within 3 months of randomization or patients not in high 
risk. 1,2,3
 The intervention used in all three studies was Tamoxifen 20 mg/day . The treatment 
groups were compared to the control groups who were given placebo. The main outcome 
measured was incidence of breast cancer at 7 years, 96 months and 20 year follow-up. The 
studies were double blind, randomized and placebo controlled. 
 The study performed by Powles et al were given 20 mg/day or placebo for 8 years and 
were followed for twenty years. Treatment effect was assessed by the use of a Cox regression 
analysis and patient who developed breast cancer were identified. 3
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 The study performed by Cuzick et al randomly assigned to receive either 20 mg/day or 
placebo for 5 years. Results were calculated at 96 months follow-up and all statistical tests were 
two-sided.1
 In the study performed by Fisher et al the population was divided into two groups who 
were given either tamoxifen or placebo for five years. Estimates of the net benefit of tamoxifen 
therapy were compared by age, race and categories of predicted breast cancer risk. 2
 Key words used in the search were tamoxifen prophylaxis and breast cancer, breast 
cancer prevention. All articles were published in English and in peer-reviewed journals. Articles 
used in review were selected using search engines such as PubMed, Medline and Cochrane. All 
three articles were selected based on relevance to clinical question and if its outcome mattered to 
the patient (POEM). The studies that were used are randomized controlled studies and summary 
of statistics were reported using p-value, RRR, ARR and NNT.
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Table 1 - Demographics & Characteristics of included studies 
Study Type # Pts Age 
(yrs)
Inclusion
Criteria
Exclusion
Criteria
W/D Interventions
Powles3 Double Blind 
RTC
2,494 30-70 -Women with 
increased risk of 
breast cancer
-At least one 1st 
degree relative 
who was <50 
years when 
diagnosed
-one 1 degree 
relative with 
bilateral breast 
cancer
-Women with 
a history of 
any cancers.
22 Tamoxifen 
20mg/day
Fisher2 Double Blind 
RTC
13,388 35-59 - Women with 
increased risk
- Women with 
negative 
mammogram
- If pt had 
taken estrogen 
or 
progesterone 
replacement 
therapy within 
3 month of 
randomization
.
181 Tamoxifen 
20mg/day
Cuzick1 Double Blind 
RTC
7,145 35-70 -Women with at 
least twofold 
relative risk if 
they were 45-70 
years of age, 
fourfold relative 
risk if they were 
40-44 years of 
age, and tenfold 
risk if they were 
35-39 years of 
age.
Women that 
had any 
previous 
invasive 
cancer or 
DVT.
6 Tamoxifen
20mg/day
DeVeau, Tamoxifen and breast cancer 4
OUTCOME MEASURED
 The primary outcome measured was the incidence of breast cancer after tamoxifen 
prophylaxis was administered. IBIS -I trial measured outcome based on 96 month follow up after 
randomization. Relative risks were computed as the ratio of incidence rates and  randomization 
was performed by telephone or fax at the IBIS center.  Incidence rates were calculated by 
dividing the number of observed events by the number of women-years of follow-up, which 
continued until the development of breast cancer, death, or cutoff date for analysis. 1
 P-1 Study measured outcome by calculating rates of breast cancer and were compared by 
the use of risk ratios and 95% confidence interval. Estimate of the benefit from 5 years of 
tamoxifen therapy was then compared by age, race and categories. 2
 The primary outcome of Royal Marsden prevention trial was occurrences of breast 
cancer. Survival was assessed by the use of a Cox proportional hazards model, all tests were two-
sided. 3
RESULTS
 Three double randomized controlled trials were analyzed in this review. All participants 
were healthy women with no evidence of breast cancer and with increased risk of developing one 
because of their family medical history of breast cancer. Patients with history of any cancer , 
deep vein thrombosis or pulmonary embolism were also excluded from the trial. 1,2,3
 In Powles, et al., 186 women developed invasive breast cancer, 82 that were on 
tamoxifen and 104 that were on placebo. This difference is not statistically significant (p=0.1). 
Results were reported at twenty-year follow-up.  The absolute risk reduction (ARR) was 
calculated at 1.4% and the relative risk reduction (RRR) was 6.4%. In this study it was 
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determined that the number needed to treat (NNT) was 71 indicating that intervention is not 
effective. (Table 2)
 Fisher et al., reported rates of breast cancer at 2.2% in tamoxifen group and 3.8% in the 
placebo group, respectively.  These results were calculated at seven year follow-up. After 7 years 
results show that the difference in results  is statistically  significant (p= <.001). The risk ratio 
(ARR) was calculated to be 1.6% and the relative risk reduction (RRR) was 73%. This study 
determined that the number to treat (NNT) was 63. The effectiveness of tamoxifen was also 
assessed by comparing the rates of developing cancer each year during years 2-5. In the year 6 
the reduction was 29% but in the year 7 it was only 14%.
 Cuzick et al., reported that prophylactic effect of tamoxifen was fairly consistent for the 
entire follow-up period and no reduction of benefit was observed for up to 10 years after 
randomization. At 96 months after randomization, 142 (5.4 %) breast cancers were diagnosed in 
tamoxifen group and 195 (3.9%) in placebo group. This difference is also statistically significant 
(p=0.004). The ARR was calculated to be 1.5% and the RRR was 0.28 %. The number needed to 
treat (NNT) in this study was determined to be 66.
Table 2 -Efficacy of Tamoxifen prophylaxis in reducing the incidence of breast cancer.
Study CER EER RRR ARR NNT 95%Cl p-value
Royal Marsden 7.8% 9.2% 17.9% 1.4% 71 0.58-1.04 0.1
National surgical 
adjuvant Breast and 
Bowel Project P-1 
Study
2.2% 3.8% 73% 1.6% 63 0.46-0.70 0.001
IBIS-I Trial 5.4% 3.9% -0.28% -1.5% -66 0.58-0.91 0.004
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DISCUSSION
 Tamoxifen is usually used to treat metastatic cancer, and to also treat breast cancer in 
certain patients after surgery. Now tamoxifen is also used in reducing the chances of breast 
cancer in women with high risk, such as family history of breast cancer.  A major problem with 
tamoxifen is deciding whether benefit to the patient is greater than risk of taking it. 7 One of the 
problems with using tamoxifen in older people is that it was only studied in younger population, 
therefore it is unknown whether tamoxifen will work exactly the same way it does in younger 
adults. 8 In IBIS-I trial it was also discovered that tamoxifen therapy can increase risk of 
cardiovascular and thromboembolic events so as endometrial cancer. However, according to 
FDA tamoxifen is currently approved in use of preventing recurrence of breast cancer and it was 
concluded that tamoxifen benefits outweigh risk in women already diagnosed with breast cancer. 
The use of tamoxifen for prevention of breast cancer  is currently used as an “off-label” and it is 
up to physician and the patient to make the determination whether they have enough confidence 
that the benefit would outweigh not only know risks but also the ones that are unknown at this 
time. 7
CONCLUSION
  According to Royal Marsden trial it was concluded that it was not statistically 
significant to demonstrate efficacy of tamoxifen in preventing invasive breast cancer in women 
at high risk. It did show significant reduction in the incidence of ER-positive breast cancer. There 
was also some limitations noted, this study was a single- institute, small study and participants 
were younger with stronger family history of breast cancer than those in other trials. 3
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Based on Cuzick et al., and Fisher et al., it can be concluded that tamoxifen prophylaxis is 
effective in reducing the incidence of breast cancer in women who are at high risk. According to 
Cuzick et al., the risk reducing effect appears to persist for at least 10 years , but the adverse 
effects do not continue after 5 year treatment period.
It was also indicated that the thromboembolic events and endometrial cancers were confined to 
the treatment period only. 1
 Future research should be designed to compare tamoxifen prophylaxis vs prophylactic 
mastectomy . The research should implement the efficacy and safety one over the other 
preventive measures. 
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